This Article Full Text Full Text (PDF) Supplementary Data Correction (v69,p8216) Correction (v69,p8216) All Versions of this Article: 0008-5472.CAN-09-1077v1 69/18/7311    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Liu, D. Articles by Xing, M. PubMed PubMed Citation Articles by Liu, D. Articles by Xing, M.

Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin

¹ Division of Endocrinology and Metabolism, the Johns Hopkins University School of Medicine, Baltimore, Maryland and ² Breast Cancer Program, Karmanos Cancer Institute, Detroit, Michigan

Requests for reprints: Michael Mingzhao Xing, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD 21287. Phone: 410-502-6888; Fax: 410-955-8172; E-mail: mxing1{at}jhmi.edu.

Key Words: thyroid cancer • PI3K/Akt pathway • genetic alteration • perifosine • temsirolimus

We investigated the genotype-dependent therapeutic potential of targeting the phosphoinositide 3-kinase (PI3K)/Akt pathway for thyroid cancer. Proliferation of TPC1, Hth7, FTC133, OCUT1, K1, and BCPAP cells that harbored PI3K/Akt-activating genetic alterations was potently inhibited by the Akt inhibitor perifosine, whereas SW1736, Hth74, WRO, KAT18, and TAD2 cells that harbored no genetic alterations had no or only modest responses. Inhibition of Akt phosphorylation by perifosine was seen in these cells. Genetic-dependent apoptosis was induced by perifosine in cells selectively tested. Similarly, potent inhibition of cell proliferation by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus occurred in virtually all the cells harboring genetic alterations, whereas modest inhibition was seen in some of the cells not harboring genetic alterations. Temsirolimus inhibited the phosphorylation of p70S6K, a substrate of mTOR. Knockdown of Akt1/2 or mTOR by shRNA approach inhibited the proliferation and colony formation of FTC133 and OCUT1 cells that harbored genetic alterations in the PI3K/Akt pathway but had no effect on SW1736 and KAT18 cells that did not. Transfection with PIK3CA mutants greatly sensitized SW1736 cells to perifosine and temsirolimus. Growth of xenograft tumors derived from FTC133 cells but not SW1736 cells in nude mice was dramatically inhibited by perifosine. Thus, this work for the first time shows that genetic alterations in the PI3K/Akt pathway confer thyroid cancer cells addiction to this pathway and their sensitivity to inhibition by targeting Akt and mTOR. This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies. [Cancer Res 2009;69(18):7311–9]

This article has been cited by other articles:

				P. Hou, E. Bojdani, and M. Xing Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 820 - 828. [Abstract] [Full Text] [PDF]

				M. Xing Identifying Genetic Alterations in Poorly Differentiated Thyroid Cancer: A Rewarding Pursuit J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4661 - 4664. [Full Text] [PDF]

				Correction: Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin Cancer Res., October 15, 2009; 69(20): 8216 - 8216. [Full Text] [PDF]